

MMWR

MORBIDITY AND MORTALITY WEEKLY REPORT

- 317 ACIP: Prevention and Control of Influenza
331 Update: Measles — Canada, 1986
334 Classification System for HTLV-III/LAV Infections

Recommendations of the Immunization Practices Advisory Committee (ACIP)

Prevention and Control of Influenza

These recommendations of the Immunization Practices Advisory Committee update for 1986-1987 the information on the vaccine and antiviral agent available for control of influenza (superseding MMWR 1985;34:261-8, 273-5). Changes include addition of statements about: (1) updating of the influenza strains in the vaccine for 1986-1987; (2) immunization and amantadine prophylaxis for household members who provide home care for high-risk persons; (3) optimal time for conducting routine vaccination programs; (4) concurrent administration of influenza vaccine and childhood vaccines; (5) immunization of children receiving long-term aspirin therapy; and (6) other sources of information about influenza and control measures.

INTRODUCTION

Influenza A viruses are classified into subtypes based on two antigens: hemagglutinin (H) and neuraminidase (N). Three subtypes of hemagglutinin (H1, H2, H3) and two subtypes of neuraminidase (N1, N2) are recognized among influenza A viruses that have caused widespread human disease. Immunity to these antigens, especially hemagglutinin, reduces the likelihood of infection and the severity of disease if infection does occur. However, there may be sufficient antigenic variation (antigenic drift) within the same subtype over time, so that infection or vaccination with one strain may not induce immunity to distantly related strains of the same subtype. Although influenza B viruses have shown much more antigenic stability than influenza A viruses, antigenic variation does occur. For these reasons, major epidemics of respiratory disease caused by new variants of influenza continue to occur, and the antigenic characteristics of current strains provide the basis for selecting virus strains included in each year's vaccine.

Typical influenza illness is characterized by abrupt onset of fever, sore throat, and nonproductive cough and, unlike many other common respiratory infections, can cause extreme malaise lasting several days. More severe disease can result from invasion of the lungs by influenza virus (primary viral pneumonia) or from secondary bacterial pneumonia. High attack rates of acute illness and the occurrence of lower respiratory tract complications usually result in dramatic increases in visits for outpatient care in physicians' offices, walk-in clinics, and emergency rooms by persons of all ages.

Individuals at high risk for influenza are poorly able to cope with the disease because of their ages or underlying health problems. Such high-risk persons are more likely to require

ACIP: Influenza — Continued

hospitalization if infected. In one recent study, for example, hospitalization rates for adults with high-risk medical conditions increased during major epidemics by about twofold to fivefold in different age groups, reaching a maximum rate of about 800 excess hospitalizations per 100,000 high-risk persons. During influenza epidemics, normally healthy children and adults may also be hospitalized for influenza-related complications, but the relative increase in hospitalization rates is much less than for the high-risk groups.

A further indication of the impact of influenza epidemics is the significant increase in mortality that often occurs. Such excess mortality is not only a direct result of pneumonia, but also of cardiopulmonary or other chronic diseases that are exacerbated during influenza infection. Ten thousand or more excess deaths have been documented during each of 18 different epidemics from 1957 to 1985, with more than 40,000 excess deaths in each of several recent epidemics. Excess mortality was again documented during the 1985-1986 influenza season. Approximately 80%-90% of the excess deaths attributed to pneumonia and influenza during epidemics have occurred among persons 65 years of age or older, although influenza-associated deaths among children or previously healthy adults under 65 years of age are reported during major epidemics.

Because of the increasing proportion of elderly persons in the U.S. population, and because age and its associated chronic diseases are risk factors for severe influenza illness, the future toll from influenza may increase unless control measures are used more vigorously than in the past. Younger populations at high risk for influenza-related complications are also increasing, due to such factors as the success of intensive-care units for neonates; better management of diseases, such as cystic fibrosis; and better survival rates for organ-transplant recipients.

OPTIONS FOR THE CONTROL OF INFLUENZA

The two presently available control measures for influenza are immunoprophylaxis with vaccines and chemoprophylaxis or therapy with the antiviral drug, amantadine hydrochloride (Symmetrel®).

Vaccination of high-risk persons each year before the influenza season is the single most important influenza-control measure. Vaccination is likely to be highly cost-effective because (1) it is targeted at individuals for whom infection may have the most severe consequences and for whom there is often a higher-than-average potential for infection, and (2) it may be administered when such high-risk individuals routinely have contact with the health-care delivery system before the influenza season for causes other than acute respiratory infection, thereby permitting vaccine administration without special visits to physicians' offices or clinics. Recent reports indicate that achieving high vaccination rates in closed populations appears to induce herd immunity when there is a good match between vaccine and epidemic strains of virus. When outbreaks of influenza A do occur in closed populations, they may be stopped by amantadine prophylaxis of all residents. Other indications for prophylaxis (whether with vaccine or antiviral drug) include the strong desire of individuals to avoid influenza infection, reduce the severity of disease, or reduce their chances of transmitting influenza to high-risk persons with whom they have frequent contact in medical-care settings or at home.

Specific therapy for influenza A by treatment with amantadine is most likely to benefit individuals who promptly seek medical attention because of the abrupt onset of an acute respiratory infection with troublesome symptoms during an influenza A epidemic. For high-risk individuals for whom influenza vaccine has not been used or has not prevented infection, early treatment with amantadine should be effective in reducing the severity and duration of illness.

Influenza is known to cause nosocomial infections, and measures, such as isolating ill patients individually or in groups, limiting visitors, and avoiding elective admissions and surgery during an influenza outbreak, have been suggested to limit further virus transmission within

ACIP: Influenza — Continued

institutions or hospitals. However, unlike amantadine use for outbreak control during influenza A epidemics, the effectiveness of these measures has not been demonstrated. Likewise, the effect on virus transmission of occasionally closing schools or classrooms during explosive outbreaks has not been established.

INACTIVATED VACCINE FOR INFLUENZA TYPES A AND B

Influenza vaccines are made from highly purified egg-grown viruses that have been rendered noninfectious ("inactivated"). Most vaccines distributed in the United States have been chemically treated ("split virus" preparations) to reduce the incidence of febrile reactions among children. Influenza vaccine contains three virus strains (two type A and one type B) representing influenza viruses presently circulating in the world and believed likely to occur in the United States next winter. The potency of present vaccines is such that (1) minimal systemic or febrile reactions are caused by the vaccine, but (2) nearly all vaccinated young adults develop hemagglutination-inhibition antibody titers likely to protect them against infection by strains like those in the vaccine and, often, by related variants that emerge. The elderly, the very young, and patients with certain chronic diseases may develop lower postvaccination antibody titers than young adults and thus be more susceptible to upper respiratory tract infection. Under these circumstances, however, influenza vaccine can still be effective in preventing lower respiratory tract involvement or other complications of influenza. Influenza vaccine will not prevent primary illnesses caused by other respiratory pathogens.

RECOMMENDATIONS FOR USE OF INACTIVATED VACCINE

Influenza vaccine is recommended for high-risk persons 6 months of age or older (see below), for their medical-care personnel and primary providers of care in the home setting, for children receiving long-term aspirin therapy, and for other persons wishing to reduce their chances of acquiring influenza illness. Vaccine composition for 1986-1987 and doses are given in Table 1. Guidelines for the use of vaccine are given below for different segments of

TABLE 1. Influenza vaccine* dosage, by patient age — United States, 1986-1987 season

Age group	Product†	Dosage‡	No. doses	Route¶
6-35 mos.	Split virus only	0.25 ml	2**	IM
3-12 yrs.	Split virus only	0.5 ml	2**	IM
> 12 years	Whole or split virus	0.5 ml	1	IM

*Contains 15 µg each of A/Chile/1/83(H1N1), A/Mississippi/1/85(H3N2), and B/Ann Arbor/1/86 hemagglutinin antigens in each 0.5 ml. Manufacturers include Parke-Davis (Fluogen® split), Squibb-Connaught (Fluzone® whole or split), Wyeth Laboratories (Influenza Virus Vaccine, Trivalent® split). Manufacturer's phone numbers to obtain further product information are: Parke-Davis—(800) 223-0432; Squibb-Connaught—(800) 822-2463; Wyeth—(800) 321-2304.

†Because of the lower potential for causing febrile reactions, only split (subvirion) vaccine should be used in children. Immunogenicity and reactogenicity of split and whole virus vaccines are similar in adults when used according to the recommended dosage.

‡Due to the accessibility of children at times when pediatric vaccines are administered, it may be desirable to simultaneously administer, particularly to high-risk children, influenza vaccine at the same time as routine pediatric vaccines or pneumococcal polysaccharide vaccine, but in different sites. Although studies have not been done, no diminution of immunogenicity or enhancement of adverse reactions should be expected.

¶The recommended site of vaccination is the deltoid muscle for adults and older children. The preferred site for infants and young children is the anterolateral aspect of the thigh.

**Two doses are recommended for maximum protection, with at least 4 weeks between doses. However, if the individual received at least one dose of influenza vaccine recommended from 1978-1979 to 1984-1985, one dose is sufficient.

ACIP: Influenza — Continued

the population. *Remaining 1985-1986 vaccine should not be used.* Although the current influenza vaccine often contains one or more antigens used in previous years, immunity declines during the year following vaccination. *Therefore, a history of vaccination in any previous year with a vaccine containing one or more antigens included in the current vaccine does not preclude the need for revaccination for the 1986-1987 influenza season to provide optimal protection.*

During the past decade, data on influenza vaccine immunogenicity and side effects were generally obtained when vaccine was administered by the intramuscular route. Because of a lack of adequate evaluation of recent influenza vaccines administered by other routes to high-risk persons, the preferred route of vaccination is intramuscular. The recommended site of vaccination is the deltoid muscle for adults and older children and the anterolateral aspect of the thigh for infants and young children.

High-Priority Target Groups for Special Vaccination Programs

1. **Groups at greatest medical risk of influenza-related complications.** Based on observations of morbidity and mortality, high-risk groups have been classified on the basis of priority, so available resources can be particularly directed toward organizing special programs to provide vaccine to those who may derive the greatest benefit. Active, targeted vaccination efforts are most necessary for the following two high-risk groups, with the objective of vaccinating at least 80% of each group.

- a. Adults and children with chronic disorders of the cardiovascular or pulmonary systems that are severe enough to have required regular medical follow-up or hospitalization during the preceding year.
- b. Residents of nursing homes and other chronic-care facilities (i.e., institutions housing patients of any age with chronic medical conditions).

2. **Groups at moderate medical risk of influenza-related complications.** After considering the needs of the above two target groups (1a and 1b), programs are desirable that make vaccine readily available to persons at moderately increased risk of serious illness compared with the general population. These include:

- a. Otherwise healthy individuals 65 years of age or older.
- b. Adults and children with chronic metabolic diseases (including diabetes mellitus), renal dysfunction, anemia, immunosuppression, or asthma that are severe enough to require regular medical follow-up or hospitalization during the preceding year.
- c. Children receiving long-term aspirin therapy, who may be at risk of developing Reye syndrome following influenza infection.

3. **Groups potentially capable of nosocomial transmission of influenza to high-risk persons.** During many winters, nosocomial outbreaks of influenza are reported. Although not proven, it is reasonable to believe that medical personnel who provide care to high-risk persons in health-care facilities, or family members, volunteer workers, or others who are the primary providers of care to a high-risk person in the home setting, can transmit influenza infections to high-risk patients while they are themselves incubating infection, undergoing subclinical infection, or working despite the existence of mild symptoms. The potential for introducing influenza to high-risk persons should be reduced by vaccinating:

- a. Physicians, nurses, and other personnel who have extensive contact with high-risk patients (e.g., primary-care and certain specialty clinicians, staff of intensive-care units, particularly neonatal intensive-care units).
- b. Providers of care to high-risk persons in the home setting (e.g., family members, visiting nurses, volunteer workers).

ACIP: Influenza - Continued**Vaccination of Other Groups**

1. General population. Physicians should administer vaccine to any person who wishes to reduce his/her chances of acquiring influenza infection. Persons who provide essential community services, such as employees of fire and police departments, are not considered at increased occupational risk of serious influenza illness but may be considered for vaccination programs designed to minimize the possible disruption of essential activities that can occur during severe epidemics.

2. Pregnant women. Pregnancy has not been demonstrated to be a risk factor for severe influenza infection, except in the largest pandemics of 1918-1919 and 1957-1958. However, a pregnant woman with a medical condition that increases her risk of complications from influenza should be vaccinated, as influenza vaccine is considered safe for pregnant women in the absence of a specific severe egg allergy. Nonetheless, when vaccine is given during pregnancy, waiting until after the first trimester is a reasonable precaution to minimize any concern over the theoretical possibility of teratogenicity. However, it may be undesirable to delay vaccination of a pregnant woman with a high-risk condition who will still be in the first trimester of pregnancy when influenza activity usually begins.

Persons Who Should Not Be Vaccinated

Inactivated influenza vaccine should not be given to persons who have an anaphylactic sensitivity to eggs (see below, **Side Effects and Adverse Reactions**). Persons with acute febrile illnesses usually should not be vaccinated until their temporary symptoms have abated.

Timing of Influenza Vaccination Activities

The first sporadic laboratory-confirmed cases of influenza in the United States or U.S. territories are often documented in September or October; however, except in years of pandemic influenza (e.g., 1957 and 1968), high levels of influenza activity have not occurred in the contiguous United States before late December. Therefore, organized vaccination campaigns where high-risk persons are routinely accessible, such as in chronic-care facilities or work-sites, may be optimally undertaken in November. Vaccination is desirable in September or October (1) if warranted by regional experience of earlier-than-normal epidemic activity (e.g., in Alaska); (2) for hospitalized high-risk patients who should be vaccinated at the time of discharge (such patients should be vaccinated when discharged from September to the time influenza activity begins to decline in their community); or (3) for other persons recommended for vaccination who receive medical check-ups or treatment during the late or early fall and who may not be seen again until after November.

Children who have not been previously vaccinated require two doses of vaccine with at least 1 month between doses. Programs for childhood influenza vaccination should be scheduled so the second dose can be given before December. Vaccine can be given to both children and adults up to and even after influenza virus activity is documented in a region, although temporary chemoprophylaxis may be indicated when influenza outbreaks are occurring (see below, **ANTIVIRAL AGENT FOR INFLUENZA A: AMANTADINE**).

Strategies for Implementing Influenza Vaccine Recommendations

More effective programs for giving influenza vaccine to high-risk persons, well planned in advance, are needed in nursing homes and other chronic-care facilities, in physicians' offices, health-maintenance organizations, hospital settings, and employee-health clinics. Adults and children in high-priority target groups who do not reside in nursing homes or other chronic-care facilities should be scheduled to receive influenza vaccine at the time of their last regular medical follow-up before the influenza season (i.e., before December). High-risk persons not scheduled for regular medical appointments in the fall should be notified by their medical-care

ACIP: Influenza — Continued

provider to come in specifically to receive influenza vaccine. Hospital discharge procedures each September-February should include influenza vaccination of high-risk patients. Medical-care personnel and auxiliary staff must be made aware of the importance of ensuring that no high-risk patient resides in or leaves a medical-care facility in the fall without being strongly urged to receive influenza vaccine and having the vaccine offered.

Educational materials (e.g., audio-visual tape) about influenza and its control are available for inservice training through state chapters of the American Lung Association (National Headquarters telephone [212] 315-8700). Black-and-white layouts that can be used to reproduce a brochure, "What You Should Know About Flu and Flu Shots," prepared by CDC, and copies of a report, "Implementation of Recommendations for Influenza Control," published in the *MMWR* (1985;34:639-43), are available on request by sending a preaddressed mailing label to: Office of Public Inquiries, Building 1, Room B63, CDC, Atlanta, Georgia 30333.

Side Effects and Adverse Reactions

Because vaccines contain only noninfectious viruses, they cannot cause influenza. Occasional cases of respiratory disease following vaccination represent coincidental illnesses unrelated to influenza infection. The most frequent side effect of vaccination, which occurs in less than one-third of vaccinees, is soreness around the vaccination site for up to 1-2 days.

Systemic reactions have been of two types:

1. Fever, malaise, myalgia, and other systemic symptoms of toxicity that, although infrequent, most often affect persons, such as young children, who have had no exposure to the influenza virus antigens contained in the vaccine. These reactions begin 6-12 hours after vaccination and can persist for 1-2 days.
2. Immediate, presumably allergic, responses, such as flare and wheal or various respiratory tract symptoms of hypersensitivity, that may occur extremely rarely after influenza vaccination. These symptoms probably result from sensitivity to some vaccine component—most likely residual egg protein. Although current influenza vaccines contain only a small quantity of egg protein, the vaccine is presumed capable of inducing hypersensitivity reactions in individuals with anaphylactic hypersensitivity to eggs, and such persons should *not* be given influenza vaccine. This includes individuals who, after eating eggs, develop swelling of the lips or tongue or experience acute respiratory distress or collapse or persons who have a documented IgE-mediated hypersensitivity reaction to eggs, including those who, from occupational exposure to egg protein, have developed evidence of occupational asthma or other allergic response. Unlike the 1976 swine influenza vaccine, subsequent vaccines, which have been prepared from other virus strains, have not been associated with an increased frequency of Guillain-Barré syndrome. Although it has been reported that influenza vaccination may inhibit the clearance of warfarin and theophylline, further studies have consistently failed to show any adverse effects of influenza vaccination in patients taking these drugs.

Simultaneous Administration of Other or Childhood Vaccines

There is considerable overlap in the target groups for influenza and pneumococcal vaccination. Pneumococcal and influenza vaccines can be given at the same time at different sites without increased side effects, but it should be emphasized that, whereas influenza vaccine is given annually, pneumococcal vaccine should be given only once. Detailed immunization records, which should be provided to each patient, will help ensure that additional doses of pneumococcal vaccine are not given.

Because children are accessible at times when pediatric vaccines are administered, it may be desirable to simultaneously administer influenza vaccine, if indicated, with routine pediatric

ACIP: Influenza — Continued

vaccine but at different sites. Although studies have not been done, no diminution of immunogenicity or enhancement of adverse reactions should be expected.

ANTIVIRAL AGENT FOR INFLUENZA A: AMANTADINE

The only drug currently approved in the United States for the specific prophylaxis and therapy of influenza virus infections is amantadine hydrochloride (Symmetrel®). This drug appears to interfere with the uncoating step in the virus replication cycle and also reduces virus shedding. Amantadine is 70%-90% effective in preventing illnesses caused by circulating strains of type A influenza viruses, but *it is not effective against type B influenza*. When administered within 24-48 hours after onset of illness, amantadine has been shown to reduce the duration of fever and other systemic symptoms with a more rapid return to routine daily activities and improvement in peripheral airway function. Since it may not prevent actual infection, persons who take the drug may still develop immune responses that will protect them when exposed to antigenically related viruses.

Considerable evidence shows that amantadine chemoprophylaxis is effective against influenza A; however, under most circumstances, it should not be used in lieu of vaccination because (1) it confers no protection against influenza B and (2) patient compliance could be a problem for continuous administration throughout epidemic periods, which generally last 6-12 weeks. Optimal use of amantadine will be improved by increasing the availability of rapid viral diagnostic tests and improving the dissemination of information about where influenza A virus infections have been confirmed by laboratory diagnosis. Such information is now available to public health officials by computer telecommunication from CDC, in addition to being reported throughout the influenza season in the *MMWR*.

Amantadine Prophylaxis Recommendations

Amantadine prophylaxis is particularly recommended to control presumed influenza A outbreaks. The drug should be given as early as possible after recognition of an outbreak in an effort to reduce the spread of the infection. *Contingency planning for influenza outbreaks in institutions is needed to establish specific steps for rapid administration of amantadine to residents of chronic-care facilities, when appropriate, including obtaining physicians' orders on short notice.* When the decision is made to give amantadine for outbreak control, it is desirable to administer the drug to all residents of the affected institution, taking into account dosage recommendations and precautions given below and in the drug's package insert. It is also recommended that amantadine prophylaxis be offered to unvaccinated staff who provide care to high-risk residents of chronic-care institutions or hospitals experiencing a presumed influenza A outbreak to reduce spread of virus and to minimize disruption of patient care.

Amantadine prophylaxis is also recommended in the following situations:

1. **As an adjunct to late immunization of high-risk individuals.** It is not too late to immunize even when influenza A is known to be in the community. However, since the development of an antibody response following vaccination takes about 2 weeks, amantadine should be used in the interim. The drug does not interfere with antibody response to the vaccine.
2. **To reduce spread of virus and maintain care for high-risk persons in the home setting.** Persons who play a major role in providing care for high-risk persons in the home setting (e.g., family members, visiting nurses, volunteer workers) should also receive amantadine for prophylaxis when influenza A virus outbreaks occur in their communities, if such persons have not been appropriately immunized.
3. **For immunodeficient persons.** To supplement protection afforded by vaccination, chemoprophylaxis is also indicated for high-risk patients who may be expected to have a poor antibody response to influenza vaccine, e.g., those with severe immunodeficiency.

ACIP: Influenza — Continued

4. For persons for whom influenza vaccine is contraindicated. Chemoprophylaxis throughout the influenza season is appropriate for those few high-risk individuals for whom influenza vaccine is contraindicated because of anaphylactic hypersensitivity to egg protein or prior severe reactions associated with influenza vaccination.

Amantadine can also be used prophylactically in other situations (e.g., unimmunized members of the general population who wish to avoid influenza A illness). This decision should be made on an individual basis.

Therapy

Amantadine should be considered for therapeutic use, particularly for persons in the high-risk groups who develop an illness compatible with influenza during known or suspected influenza A activity in the community. The drug should be given within 24-48 hours of onset of illness and should be continued until 48 hours after resolution of signs and symptoms.

Precautions for the Use of Amantadine

Special precautions should be taken when amantadine is administered to persons with impaired renal function or those with an active seizure disorder (see below). The safety and efficacy of amantadine for children under 1 year of age have not been fully established.

Dosage

The usual adult dosage of amantadine is 200 mg/day; splitting the dose into 100 mg twice daily may reduce the incidence of side effects (Table 2). Amantadine is not metabolized and is excreted unchanged in the urine. Because renal function normally declines with age, and because side effects have been reported more frequently among older persons, a reduced dosage of 100 mg/day is generally advisable for persons aged 65 years or older to minimize the risk of toxicity. Persons 10-64 years old with an active seizure disorder may also be at risk of increased frequency of seizures when given amantadine at 200 mg/day rather than 100 mg/day.

Side Effects and Adverse Reactions

Five percent to 10% of otherwise healthy adults taking amantadine report side effects such as insomnia, lightheadedness, irritability, and difficulty concentrating. These and other side effects (see package insert) may be more pronounced among patients with underlying diseases, particularly those common among the elderly; *provisions for careful monitoring are needed for these individuals so that adverse effects may be recognized promptly, and the drug reduced in dosage or discontinued, if needed. Since amantadine is not metabolized, toxic levels can occur when renal function is sufficiently impaired.*

SELECTED BIBLIOGRAPHY

- Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA, eds. Options for the control of influenza. New York: Alan R. Liss, 1986;155-68.
- Barker WH. Excess pneumonia and influenza associated hospitalization during influenza A epidemics in the U.S., 1970-78. In: Kendal AP, Patriarca PA, eds. Options for the control of influenza. New York: Alan R. Liss, 1986;75-87.
- Barker WH, Mullooly JP. Effectiveness of inactivated influenza vaccine among non-institutionalized elderly persons. In: Kendal AP, Patriarca PA, eds. Options for the control of influenza. New York: Alan R. Liss, 1986;169-82.
- Barker WH, Mullooly JP. Influenza vaccination of elderly persons. Reduction in pneumonia and influenza hospitalizations and deaths. JAMA 1980;244:2547-9.
- Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980;112:798-811.
- Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med 1982;142:85-9.
- Bukowskyj M, Munt PW, Wigle R, Nakatsu K. Theophylline clearance. Lack of effect of influenza vaccination and ascorbic acid. Am Rev Respir Dis 1984;129:672-5.

ACIP: Influenza — Continued

- Consensus Development Conference Panel. Amantadine: does it have a role in prevention and treatment of influenza? A National Institutes of Health Consensus Development Conference. *Ann Intern Med* 1980;92:256-8.
- DeStefano F, Goodman RA, Noble GR, McClary GD, Smith SJ, Broome CV. Simultaneous administration of influenza and pneumococcal vaccines. *JAMA* 1982;247:2551-4.
- Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. *N Engl J Med* 1982;307:580-4.
- Dowdle WR, Coleman MT, Gregg MB. Natural history of influenza type A in the United States, 1957-1972. *Prog Med Virol* 1974;17:91-135.
- Eickhoff TC. Immunization against influenza: rationale and recommendations. *J Infect Dis* 1971;123:446-54.
- Fedson DS, Kessler HA. A hospital-based influenza immunization program, 1977-78. *Am J Public Health* 1983;73:442-5.
- Galasso GJ, Tyeryar FJ Jr, Cate TR, et al., eds. Clinical studies of influenza vaccines—1976. *J Infect Dis* 1977;136(Suppl):S341-S742.
- Glezen WP. Serious morbidity and mortality associated with influenza epidemics. *Epidemiol Rev* 1982;4:25-44.
- Glezen WP, Six HR, Frank AL, et al. Impact of epidemics upon communities and families. In: Kendal AP, Patriarca PA, eds. Options for the control of influenza. New York: Alan R. Liss, 1986;63-73.

TABLE 2. Amantadine hydrochloride* dosage, by age of patient and level of renal function

Age group	Dosage†
No recognized renal disease	
1-9 yrs.‡	4.4-8.8 mg/kg/day once daily or divided twice daily. Total dosage should not exceed 150 mg/day.
10-64 yrs.¶	200 mg once daily or divided twice daily
≥ 65 yrs.	100 mg once daily
Recognized renal disease	
Creatinine clearance: (ml/min 1.73m ²)	
≥ 80	100 mg twice daily
60-79	200 mg/100 mg on alternate days
40-59	100 mg once daily
30-39	200 mg twice weekly
20-29	100 mg thrice weekly
10-19	200 mg/100 mg alternating every 7 days

*Amantadine hydrochloride (Symmetrel®) is manufactured and distributed by E. I. Du Pont de Nemours and Company. (Medical Department phone number 800-441-9861, or in Delaware 992-3273).

†For prophylaxis, amantadine must be taken each day for the duration of influenza A activity in the community (generally 6-12 weeks). For therapy, amantadine should be started as soon as possible after onset of symptoms and should be continued for 24-48 hours after the disappearance of symptoms (generally 5-7 days).

‡Use in children under 1 year has not been evaluated adequately.

¶Reduction of dosage to 100 mg/day is also recommended for persons with an active seizure disorder, because such persons may be at risk of experiencing an increase in the frequency of their seizures when given amantadine at 200 mg/day.

**The reduced dosage of 100 mg/day for person 65 years of age or older without recognized renal disease is recommended to minimize the risk of toxicity, because renal function normally declines with age, and because side effects have been reported more frequently in the elderly when a daily dose of 200 mg has been used.

ACIP: Influenza - Continued

- Hammond GW, Cleary M. Absenteeism among hospital staff during an influenza epidemic: implications for immunoprophylaxis. *Can Med Assoc J* 1984;131:449-52.
- Horadam VW, Sharp JG, Smilack JD, Schonberger LB. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. *Ann Intern Med* 1981;94:454-8.
- Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination. *JAMA* 1982;248:698-700.
- Kilbourne ED, ed. The influenza viruses and influenza. New York: Academic Press, 1975.
- LaMontagne JR, Noble GR, Quinnan GV, et al. Summary of clinical trials of inactivated influenza vaccine—1978. *Rev Infect Dis* 1983;5:723-36.
- Mufson MA, Krause HE, Tarrant CJ, Schiffman G, Cano FR. Polyvalent pneumococcal vaccine given alone and in combination with bivalent influenza vaccine. *Proc Soc Exp Biol Med* 1980;163:498-503.
- Nolan TF Jr, Goodman RA, Hinman AR, Noble GR, Kendal AP, Thacker SB. Morbidity and mortality associated with influenza B in the United States, 1979-1980. A report from the Center for Disease Control. *J Infect Dis* 1980;142:360-2.

(Continued on page 331)

TABLE I. Summary—cases specified notifiable diseases, United States

Disease	20th Week Ending			Cumulative, 20th Week Ending		
	May 17, 1986	May 18, 1985	Median 1981-1985	May 17, 1986	May 18, 1985	Median 1981-1985
Acquired Immunodeficiency Syndrome (AIDS)	210	188	N	4,762	2,855	N
Asplenic meningitis	93	70	70	1,846	1,395	1,499
Encephalitis: Primary (arbovirus-borne & unspecified)	11	11	12	288	347	347
Post-infectious	3	2	2	33	53	37
Gonorrhea: Civilian	14,456	17,032	17,081	311,506	302,409	341,933
Military	433	683	587	5,996	7,444	8,406
Hepatitis: Type A	414	351	371	8,371	8,131	8,881
Type B	491	461	461	9,615	9,526	8,843
Non A, Non B	70	72	N	1,299	1,593	N
Unspecified	89	103	148	1,802	2,068	2,812
Legionellosis	10	7	N	201	229	N
Leprosy	1	1	5	105	150	84
Malaria	21	23	14	277	278	281
Measles: Total*	143	72	72	2,527	1,188	1,188
Indigenous	135	63	N	2,417	951	N
Imported	8	9	N	110	237	N
Meningococcal infections: Total	59	55	58	1,225	1,185	1,370
Civilian	59	55	58	1,223	1,181	1,367
Military	-	-	-	2	4	5
Mumps	73	56	100	1,377	1,574	1,726
Pertussis	48	37	26	929	584	584
Rubella (German measles)	13	14	28	202	189	474
Syphilis (Primary & Secondary): Civilian	459	436	591	9,791	9,523	11,555
Military	1	1	6	77	70	137
Toxic Shock syndrome	4	7	N	139	151	N
Tuberculosis	412	430	463	7,629	7,596	8,427
Tularemia	2	4	4	23	37	46
Typhoid fever	8	3	7	94	108	130
Typhus fever, tick-borne (RMSF)	18	20	26	86	81	87
Rabies, animal	112	119	137	2,096	1,908	2,315

TABLE II. Notifiable diseases of low frequency, United States

	Cum 1986		Cum 1986
Anthrax	-	Leptospirosis (Hawaii 1)	18
Botulism: Foodborne	4	Plague	-
Infant	21	Polio myelitis, Paralytic	-
Other	-	Psittacosis (Va. 1)	23
Brucellosis (Nebr. 1, Tex. 1)	22	Rabies, human	-
Cholera	-	Tetanus (Mo. 1, Calif. 1)	17
Congenital rubella syndrome	2	Trichinosis (Iowa 1)	8
Congenital syphilis, ages < 1 year	11	Typhus fever, flea-borne (endemic, murine) (Tex. 1)	10
Diphtheria	-		

*Four of the 143 reported cases for this week were imported from a foreign country or can be directly traceable to a known internationally imported case within two generations.

TABLE III. Cases of specified notifiable diseases, United States, weeks ending
May 17, 1986 and May 18, 1985 (20th Week)

Reporting Area	AIDS Cum 1986	Aseptic Mening- itis 1986	Encephalitis		Gonorrhea (Civilian)		Hepatitis (Viral), by type				Legionel- losis 1986	Leptosis Cum 1986
			Primary	Post-in- fectious	Cum 1986	Cum 1985	A	B	NA/NB	Unspec- ified		
			Cum 1986	Cum 1985	Cum 1986	Cum 1985	1986	1986	1986	1986		
UNITED STATES	4,782	93	288	33	311,505	302,409	414	491	70	89	10	105
NEW ENGLAND	195	1	9	2	7,056	9,250	9	22	3	4	-	3
Maine	9	-	-	-	376	356	-	-	-	-	-	-
NH	7	-	2	-	186	197	-	-	-	-	-	-
VT	2	-	2	1	104	98	-	1	-	-	-	-
Mass	111	-	2	-	3,083	3,437	7	13	1	3	-	3
R.I.	13	1	-	-	673	696	-	2	-	-	-	-
Conn	53	-	3	1	2,633	4,466	2	6	2	1	-	-
MID ATLANTIC	1,823	4	47	1	53,211	42,909	23	38	6	22	-	9
Upstate N.Y.	164	-	18	-	6,028	6,193	6	9	3	-	-	1
N.Y. City	1,272	4	11	-	30,781	19,861	5	2	-	17	-	7
N.J.	300	-	5	-	7,138	7,922	5	20	3	5	-	-
Pa.	87	-	13	1	9,264	8,933	7	7	-	-	-	1
E.N. CENTRAL	253	11	58	4	40,050	43,444	23	63	1	3	2	4
Ohio	30	1	18	2	9,542	11,270	12	20	-	-	1	-
Ind	26	-	5	2	4,831	4,122	5	13	-	-	-	-
Ill.	128	-	12	-	10,823	12,037	-	3	-	-	-	3
Mich	55	10	22	-	12,816	12,382	6	27	-	3	1	1
Wis.	14	-	1	-	2,038	3,673	-	-	-	-	-	-
W.N. CENTRAL	84	3	9	6	13,497	14,953	26	25	5	2	1	1
Minn	39	-	5	-	1,998	2,201	3	1	-	-	-	1
Iowa	7	1	4	-	1,373	1,603	2	1	-	-	-	-
Mo.	20	-	-	-	6,923	6,981	13	21	4	2	-	-
N. Dak.	2	-	-	-	127	107	-	-	-	-	-	-
S. Dak.	1	1	-	-	281	274	2	-	-	-	-	-
Nebr.	3	-	-	-	930	1,438	-	2	1	-	-	-
Kans.	12	1	-	6	1,865	2,349	6	-	-	-	1	-
S. ATLANTIC	690	17	45	13	76,795	65,254	53	107	14	9	4	1
Del.	12	-	3	-	1,314	1,457	2	-	-	-	-	-
Md.	77	1	11	-	9,176	10,494	2	19	6	2	-	-
D.C.	90	-	-	-	6,152	5,411	-	-	-	-	-	-
Va.	70	4	16	1	6,727	6,904	1	14	2	1	-	1
W. Va.	2	-	6	-	952	967	10	3	-	-	-	-
N.C.	28	1	8	1	13,410	11,956	-	12	1	-	2	-
S.C.	17	1	-	-	7,081	8,124	-	10	-	-	-	-
Ga.	87	4	-	-	9,359	-	4	11	-	-	-	-
Fla.	307	6	1	11	22,624	19,941	34	38	5	6	2	-
E.S. CENTRAL	47	7	19	1	26,306	26,113	10	38	4	-	-	-
Ky.	12	-	8	-	3,024	2,875	1	12	2	-	-	-
Tenn.	20	2	1	1	10,270	10,386	1	13	1	-	-	-
Ala.	10	4	9	-	7,457	8,283	8	8	1	-	-	-
Miss.	5	1	1	-	5,555	4,569	-	5	-	-	-	-
W.S. CENTRAL	356	17	29	1	38,947	42,439	38	31	5	20	2	7
Ark.	14	1	-	-	3,615	4,040	3	4	-	2	-	-
La.	58	1	2	-	7,048	8,652	2	5	3	-	-	-
Okla.	16	3	6	-	4,541	4,414	5	5	1	-	-	-
Tex.	268	12	21	1	23,743	25,333	28	17	1	18	2	7
MOUNTAIN	123	6	12	1	9,828	9,728	65	38	5	11	1	7
Mont.	3	-	-	1	251	289	1	-	-	-	-	-
Idaho	2	-	-	-	313	331	1	3	-	-	-	-
Wyo.	2	-	2	-	201	249	1	-	-	-	-	-
Colo.	65	2	2	-	2,585	2,983	7	5	1	4	-	3
N. Mex.	6	-	1	-	1,006	1,156	3	2	1	2	-	-
Ariz.	29	3	5	-	3,279	2,757	47	21	1	4	-	2
Utah	6	-	1	-	410	411	2	2	-	-	1	-
Nev.	11	1	1	-	1,803	1,552	3	5	2	-	-	2
PACIFIC	1,191	27	60	4	45,816	48,319	167	129	27	18	-	73
Wash.	34	3	5	-	3,492	3,330	1	11	3	5	-	7
Oreg.	24	-	-	-	1,826	2,427	17	10	6	1	-	-
Calif.	1,114	21	53	4	38,804	40,692	148	106	18	12	-	57
Alaska	9	1	2	-	1,162	1,142	1	-	-	-	-	-
Hawaii	10	2	-	-	532	728	-	2	-	-	-	9
Guam	-	-	-	-	47	73	-	-	-	-	-	1
P.R.	48	-	3	-	858	1,444	3	8	-	1	-	7
V.I.	1	-	-	-	84	183	-	-	-	-	-	-
Pac. Trust Terr.	-	-	-	-	72	322	-	-	-	-	-	1
Amer Samoa	-	-	-	-	14	-	-	1	-	-	-	1

N Not notifiable

U Unavailable

TABLE III. (Cont'd.) Cases of specified notifiable diseases, United States, weeks ending
May 17, 1986 and May 18, 1985 (20th Week)

Reporting Area	Measles (Rubella)		Meningococcal infections		Mumps		Pertussis		Rubella						
	Indigenous		Imported *		Total		Total		Total						
	Cum. 1986	1986	Cum. 1986	1986	Cum. 1986	1986	Cum. 1986	1986	Cum. 1986	1986	Cum. 1986				
UNITED STATES	277	135	2,417	8	110	1,188	1,225	73	1,377	48	929	584	13	202	189
NEW ENGLAND	15	-	18	-	-	97	88	-	35	1	46	28	1	2	6
Mass.	-	-	-	-	-	-	18	-	-	-	2	2	-	-	-
N.H.	-	-	-	-	-	-	3	-	10	-	15	15	-	1	2
Vt.	1	-	-	-	-	-	13	-	-	-	2	2	-	-	-
Mass.	9	-	15	-	-	95	17	-	1	-	11	4	-	-	4
R.I.	2	-	1	-	-	-	11	-	6	-	1	3	-	-	-
Conn.	3	-	-	-	-	2	24	-	18	1	15	2	1	1	-
MID ATLANTIC	32	51	947	-	11	92	193	3	79	1	93	62	-	26	43
Upstate N.Y.	7	-	7	-	10	44	63	1	31	-	62	32	-	18	8
N.Y. City	10	15	188	-	1	28	38	-	5	-	3	9	-	5	16
N.J.	3	34	767	-	-	7	27	2	19	-	6	1	-	3	7
Pa.	12	2	5	-	-	13	65	-	24	1	22	20	-	-	12
E.N. CENTRAL	10	27	307	1	4	366	180	44	697	5	154	83	1	10	19
Ohio	2	-	-	-	-	43	71	20	78	2	85	14	-	-	-
Ind.	-	-	-	-	-	1	17	-	16	-	16	11	-	-	-
Ill.	4	27	183	1	1	220	35	8	363	-	18	12	-	6	5
Mich.	4	-	-	-	-	50	36	14	127	2	20	8	1	3	13
Wis.	-	-	124	-	3	52	1	2	113	1	35	38	-	1	1
W.N. CENTRAL	6	4	120	2	13	5	65	1	57	4	50	49	-	8	10
Minn.	2	1	20	-	4	2	14	-	1	-	24	11	-	-	1
Iowa	1	-	-	-	1	-	7	1	11	3	9	3	-	-	-
Mo.	2	3	5	-	4	2	23	-	13	-	4	10	-	1	-
N. Dak.	-	-	5	-	1	-	-	-	2	-	2	6	-	-	2
S. Dak.	-	-	-	-	-	-	2	-	1	-	3	1	-	-	-
Nebr.	1	-	-	-	-	-	7	-	-	-	1	-	-	-	-
Kans.	-	-	90	2	3	1	12	-	29	1	8	17	-	7	7
S. ATLANTIC	38	4	317	1	28	150	251	5	100	19	355	146	1	7	23
Del.	-	-	1	-	-	-	1	-	-	2	207	-	-	-	-
Md.	6	2	18	-	6	20	32	-	6	-	24	58	-	-	1
D.C.	-	-	-	-	-	2	2	-	-	-	-	-	-	-	-
Va.	7	1	13	1	18	16	48	-	17	2	11	3	-	-	1
W. Va.	-	-	2	-	-	23	3	1	29	-	5	-	-	-	8
N.C.	4	-	1	-	1	1	42	2	9	3	18	8	-	-	2
S.C.	2	-	289	-	-	24	-	11	-	-	5	-	-	-	-
Ga.	4	-	2	-	1	8	36	2	10	6	71	47	-	-	-
Fla.	15	1	12	-	2	80	63	-	18	6	14	30	1	7	11
E.S. CENTRAL	6	-	1	-	-	-	70	1	16	2	18	6	-	1	1
Ky.	2	-	-	-	-	-	11	1	3	-	1	1	-	-	-
Tenn.	-	-	1	-	-	-	30	-	11	-	5	1	-	-	-
Ala.	2	-	-	-	-	-	21	-	1	2	12	2	-	-	-
Miss.	2	-	-	-	-	-	8	-	1	-	2	-	-	-	-
W.S. CENTRAL	20	24	326	1	25	71	102	4	101	1	28	72	2	37	16
Ark.	-	4	275	-	2	-	13	-	7	-	2	9	-	-	1
La.	4	-	-	-	-	7	15	-	-	-	4	2	-	-	-
Okla.	2	-	-	-	4	-	14	N	N	1	22	61	-	-	1
Tex.	14	20	51	1	19	64	60	4	94	-	-	-	2	37	14
MOUNTAIN	8	13	166	1	9	308	50	8	149	5	99	25	-	1	4
Mont.	-	-	-	-	1	134	6	-	4	1	5	3	-	-	-
Idaho	1	-	-	-	-	46	1	-	2	-	26	-	-	-	1
Wyo.	-	-	-	-	-	-	2	-	-	-	1	-	-	-	-
Colo.	1	-	2	1	4	5	9	-	6	2	23	9	-	-	-
N. Mex.	-	-	16	-	4	3	6	N	N	-	9	4	-	-	2
Ariz.	3	13	148	-	-	121	14	8	125	1	24	5	-	1	1
Utah	2	-	-	-	-	-	6	-	9	1	11	4	-	-	-
Nev.	1	-	-	-	-	-	6	-	3	-	-	-	-	-	-
PACIFIC	142	12	217	2	20	99	248	7	143	10	86	113	8	110	67
Wash.	11	-	47	-	7	1	31	-	5	7	33	18	1	3	2
Oreg.	12	-	-	-	2	3	20	N	-	-	5	17	-	-	1
Calif.	119	12	151	2	10	88	188	7	126	3	44	72	6	105	44
Alaska	-	-	-	-	-	-	8	-	4	-	1	3	-	-	-
Hawaii	-	-	19	-	1	7	1	-	8	-	3	3	1	2	20
Guam	1	-	3	-	-	10	-	-	2	-	-	-	-	-	-
P.R.	3	-	8	-	-	46	3	-	16	1	5	2	-	2	1
V.I.	-	-	-	-	-	10	-	-	7	-	-	-	-	58	9
Pac. Trust Terr.	-	-	-	-	-	-	1	-	2	-	-	-	-	-	-
Amer. Samoa	-	1	1	-	-	-	-	-	-	-	-	-	-	-	-

*For measles only, imported cases includes both out-of-state and international importations.

N Not notifiable U Unavailable † International ‡ Out-of-state

TABLE III. (Cont'd.) Cases of specified notifiable diseases, United States, weeks ending May 17, 1986 and May 18, 1985 (20th Week)

Reporting Area	Syphilis (Civilian) (Primary & Secondary)		Toxic-shock Syndrome	Tuberculosis		Tula- remia	Typhoid Fever	Typhus Fever (Tick-borne) (RMSF)	Rabies, Animal
	Cum 1986	Cum 1985		Cum 1986	Cum 1985				
UNITED STATES	9,791	9,523	4	7,629	7,596	23	94	66	2,096
NEW ENGLAND	192	213	-	238	259	-	4	1	2
Maine	11	7	-	24	18	-	-	-	-
N.H.	6	3	-	5	10	-	-	-	-
Vt.	6	-	-	9	4	-	-	-	-
Mass.	95	110	-	113	158	-	3	1	-
R.I.	12	-	-	14	21	-	-	-	1
Conn.	62	87	-	73	48	-	1	-	1
MID ATLANTIC	1,419	1,281	-	1,532	1,405	-	10	1	178
Upstate N.Y.	68	96	-	230	239	-	1	1	26
N.Y. City	773	798	-	740	711	-	5	-	1
N.J.	269	268	-	286	151	-	3	-	5
Pa.	309	119	-	276	304	-	1	-	146
E.N. CENTRAL	400	431	1	955	905	-	5	6	42
Ohio	50	56	-	163	166	-	-	6	3
Ind.	49	36	-	116	112	-	-	-	9
Ill.	217	218	-	404	393	-	-	-	15
Mich.	59	100	1	221	184	-	4	-	5
Wis.	25	21	-	51	50	-	1	-	10
W.N. CENTRAL	104	104	1	221	201	7	4	2	311
Minn.	17	26	1	53	39	-	1	-	31
Iowa	5	14	-	22	30	1	-	-	72
Mo.	55	44	-	108	96	6	3	-	33
N. Dak.	2	-	-	4	2	-	-	-	78
S. Dak.	2	4	-	10	7	-	-	-	65
Nebr.	8	-	-	4	9	-	-	-	5
Kans.	15	10	-	20	18	-	-	2	27
S. ATLANTIC	2,748	2,395	-	1,445	1,578	4	12	23	513
Del.	12	16	-	16	16	-	-	-	-
Md.	182	165	-	98	138	1	3	2	287
D.C.	132	137	-	52	73	-	1	-	-
Va.	173	127	-	135	127	1	3	6	80
W. Va.	8	4	-	47	39	-	1	1	10
N.C.	195	267	-	212	199	1	2	4	3
S.C.	273	297	-	160	181	-	-	9	13
Ge.	383	-	-	217	250	1	-	1	63
Fla.	1,390	1,382	-	508	555	-	2	-	57
E.S. CENTRAL	628	813	1	682	657	3	-	12	127
Ky.	27	32	-	176	128	2	-	1	35
Tenn.	237	244	-	192	199	1	-	5	56
Ala.	222	269	1	221	230	-	-	2	36
Miss.	142	268	-	93	100	-	-	4	-
W.S. CENTRAL	2,078	2,410	-	923	852	6	5	20	316
Ark.	98	122	-	106	87	4	-	1	73
La.	339	402	-	171	119	-	-	-	7
Dkls.	62	67	-	86	104	2	1	16	27
Tex.	1,579	1,819	-	560	542	-	4	3	209
MOUNTAIN	220	295	1	168	186	2	5	1	350
Mont.	2	1	-	7	19	-	1	-	126
Idaho	1	3	-	5	11	-	-	-	-
Wyo.	-	5	-	-	4	-	-	-	-
Colo.	71	89	-	10	18	-	-	1	165
N. Mex.	26	36	-	36	38	1	-	-	-
Ariz.	96	164	1	78	84	-	1	-	56
Utah	4	3	-	17	6	1	2	-	-
Nev.	20	14	-	15	6	-	-	-	-
PACIFIC	2,002	1,581	-	1,465	1,553	1	49	-	257
Wash.	48	55	-	78	83	-	2	-	-
Oreg.	42	33	-	50	49	-	-	-	-
Calif.	1,894	1,464	-	1,235	1,303	-	44	-	249
Alaska	-	1	-	24	50	1	1	-	8
Hawaii	18	28	-	78	68	-	2	-	-
Guam	1	2	-	30	16	-	-	-	-
P.R.	318	331	-	114	118	-	2	-	17
V.I.	-	1	-	1	1	-	-	-	-
Pac. Trust Terr.	112	22	-	10	26	-	27	-	-
Amer. Samoa	-	-	-	3	-	-	-	-	-

U: Unavailable

TABLE IV. Deaths in 121 U.S. cities,* week ending
May 17, 1986 (20th Week)

Reporting Area	All Causes, By Age (Years)						P&I** Total	Reporting Area	All Causes, By Age (Years)						P&I** Total
	All Ages	≥65	45-64	25-44	1-24	<1			All Ages	≥65	45-64	25-44	1-24	<1	
NEW ENGLAND	734	498	158	48	17	13	48	S. ATLANTIC	1,308	787	316	94	38	71	43
Boston, Mass.	230	125	69	20	10	6	24	Atlanta, Ga.	165	80	38	25	8	14	5
Bridgeport, Conn.	54	29	17	4	2	2	1	Baltimore, Md.	229	131	61	18	8	13	6
Cambridge, Mass.	25	20	3	2	-	-	2	Charlotte, N.C.	99	68	22	4	2	3	6
Fall River, Mass.	32	31	1	-	-	-	2	Jacksonville, Fla.	113	62	28	7	3	13	7
Hartford, Conn.	47	38	6	2	1	-	1	Miami, Fla.	102	63	27	5	3	4	1
Lowell, Mass.	37	29	7	1	-	-	-	Norfolk, Va.	60	38	14	2	2	4	2
Lynn, Mass.	17	11	5	1	-	-	2	Richmond, Va.	68	42	14	7	1	4	3
New Bedford, Mass.	24	20	1	3	-	-	2	Savannah, Ga.	39	20	13	4	1	1	1
New Haven, Conn.	38	26	8	2	1	1	-	St. Petersburg, Fla.	117	98	10	2	3	4	7
Providence, R.I.	79	51	18	7	1	2	7	Tampa, Fla.	63	38	14	6	2	1	4
Somerville, Mass.	4	4	-	-	-	-	1	Washington, D.C.	227	131	67	15	4	10	1
Springfield, Mass.	45	33	9	2	-	1	3	Wilmington, Del.	26	16	8	1	1	-	-
Waterbury, Conn.	33	25	6	1	1	-	1								
Worcester, Mass.	69	56	6	3	1	1	2								
MID ATLANTIC	2,684	1,722	578	226	60	78	132	E. S. CENTRAL	748	462	180	54	28	24	33
Albany, N.Y.	40	26	6	4	1	3	3	Birmingham, Ala.	141	76	37	10	9	9	2
Allentown, Pa.	24	16	4	3	1	-	-	Chattanooga, Tenn.	55	34	8	8	1	4	2
Buffalo, N.Y.	98	63	27	6	1	1	6	Knoxville, Tenn.	79	49	24	3	2	1	5
Camden, N.J.	42	28	9	-	2	3	1	Louisville, Ky.	113	78	23	5	4	3	6
Elizabeth, N.J.	31	22	7	1	1	-	2	Memphis, Tenn.	143	93	33	11	6	-	6
Erie, Pa.	47	35	9	1	1	1	3	Mobile, Ala.	53	32	12	5	2	2	4
Jersey City, N.J.	36	24	9	3	-	-	1	Montgomery, Ala.	43	27	12	2	2	-	2
N.Y. City, N.Y.	1,424	908	297	145	37	37	83	Nashville, Tenn.	121	73	31	10	2	5	6
Newark, N.J.	87	42	22	14	3	7	5	W.S. CENTRAL	1,349	808	303	142	51	44	48
Paterson, N.J.	23	15	5	1	-	2	1	Austin, Tex.	36	26	12	8	7	1	-
Philadelphia, Pa.	395	247	93	32	9	14	29	Baton Rouge, La.	41	26	7	4	2	2	-
Pittsburgh, Pa.	56	41	14	1	-	-	-	Corpus Christi, Tex.	51	29	16	5	1	-	1
Reading, Pa.	27	24	3	-	-	-	3	Dallas, Tex.	187	119	34	25	7	2	9
Rochester, N.Y.	127	89	29	6	-	3	5	El Paso, Tex.	52	32	7	5	3	5	4
Schenectady, N.Y.	1	6	6	-	-	-	1	Fort Worth, Tex.	66	53	23	11	3	6	1
Scranton, Pa.	29	18	7	1	1	2	1	Houston, Tex.	384	206	87	41	17	13	10
Syracuse, N.Y.	80	58	14	4	2	2	6	Little Rock, Ark.	73	48	12	6	1	6	6
Trenton, N.J.	30	18	9	3	-	2	-	New Orleans, La.	138	78	36	17	2	5	1
Utica, N.Y.	17	11	5	-	1	-	-	San Antonio, Tex.	155	99	38	11	6	1	13
Yonkers, N.Y.	26	21	4	-	-	1	2	Shreveport, La.	51	37	11	2	1	-	3
								Tulsa, Okla.	77	46	20	7	1	3	-
E. CENTRAL	2,361	1,487	558	183	61	91	72	MOUNTAIN	676	427	134	59	38	22	22
Akron, Ohio	80	54	17	3	2	4	-	Albuquerque, N. Mex.	78	48	18	9	3	-	1
Canton, Ohio	33	21	11	1	-	-	1	Colorado Springs, Colo.	32	22	4	2	2	2	4
Chicago, Ill.	565	360	126	46	10	23	16	Denver, Colo.	108	73	15	10	7	3	2
Cincinnati, Ohio	147	91	29	10	8	9	12	Las Vegas, Nev.	93	54	22	10	5	2	4
Cleveland, Ohio	164	96	44	15	5	4	6	Ogden, Utah	19	14	2	2	-	1	2
Columbus, Ohio	167	107	45	9	2	4	4	Phoenix, Ariz.	169	97	34	14	14	10	2
Dayton, Ohio	122	72	32	9	7	2	2	Pueblo, Colo.	18	16	1	1	-	-	3
Detroit, Mich.	226	119	60	27	6	14	5	Salt Lake City, Utah	45	29	7	4	2	3	1
Evansville, Ind.	35	25	6	3	1	-	-	Tucson, Ariz.	116	74	31	7	3	1	3
Fort Wayne, Ind.	66	45	12	3	4	2	-								
Gary, Ind.	20	9	6	3	2	-	-								
Grand Rapids, Mich.	61	41	12	1	2	5	2	PACIFIC	1,761	1,169	339	160	51	38	91
Indianapolis, Ind.	176	112	43	12	2	7	3	Berkeley, Calif.	18	13	1	3	-	1	-
Madison, Wis.	48	32	8	2	1	5	3	Fresno, Calif.	74	39	22	4	4	5	4
Milwaukee, Wis.	147	101	37	6	1	2	1	Glendale, Calif.	26	23	3	-	-	-	2
Peoria, Ill.	57	31	13	4	4	2	2	Honolulu, Hawaii	72	48	16	6	-	2	7
Rockford, Ill.	40	22	14	1	2	1	-	Long Beach, Calif.	56	43	7	2	4	-	12
South Bend, Ind.	61	40	14	2	1	3	3	Los Angeles, Calif.	508	315	103	61	20	5	16
Toledo, Ohio	98	80	16	1	-	1	7	Oakland, Calif.	70	44	15	8	2	1	3
Youngstown, Ohio	48	29	13	2	1	3	1	Pasadena, Calif.	27	19	6	-	2	-	1
								Portland, Ore.	116	83	23	8	1	1	6
W. CENTRAL	722	513	124	43	19	23	32	Sacramento, Calif.	141	100	21	11	5	4	11
Des Moines, Iowa	50	38	10	1	1	-	4	San Diego, Calif.	154	107	21	16	4	6	12
Duluth, Minn.	34	25	8	-	-	1	-	San Francisco, Calif.	131	79	32	20	-	-	2
Kansas City, Kans.	32	22	5	3	1	1	1	San Jose, Calif.	138	87	35	10	2	4	7
Kansas City, Mo.	119	85	16	6	6	5	5	Seattle, Wash.	144	103	24	7	6	4	6
Lincoln, Neb.	24	22	2	-	-	1	-	Spokane, Wash.	45	33	6	2	-	4	2
Minneapolis, Minn.	89	51	22	10	2	4	3	Tacoma, Wash.	41	33	4	2	1	1	-
Omaha, Neb.	81	63	6	8	1	3	2								
St. Louis, Mo.	149	106	27	8	4	4	6								
St. Paul, Minn.	74	52	15	2	3	2	3								
Wichita, Kans.	70	49	13	5	1	2	7								
TOTAL	12,325	7,874	2,690	989	361	404	521								

* Mortality data in this table are voluntarily reported from 121 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

** Pneumonia and influenza.

† Because of changes in reporting methods in these 3 Pennsylvania cities, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

†† Total includes unknown ages.


§ Data not available. Figures are estimates based on average of past 4 weeks.

ACIP: Influenza — Continued

- Patriarca PA, Kendal AP, Stricof RL, Weber JA, Meissner MK, Dateno B. Influenza vaccination and warfarin or theophylline toxicity in nursing home residents [Letter]. *N Engl J Med* 1983;308:1601-2.
- Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic. *JAMA* 1985;253:1136-9.
- Parkman PD, Galasso GJ, Top FH Jr, Noble GR. Summary of clinical trials of influenza vaccines. *J Infect Dis* 1976;134:100-7.
- Wright PF, Dolin R, La Montagne JR. Summary of clinical trials of influenza vaccines-II. *J Infect Dis* 1976;134:633-8.
- Younkin SW, Betts RF, Roth FR, Douglas RG Jr. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. *Antimicrob Agents Chemother* 1983;23:577-82.

*International Notes***Update: Measles — Canada, 1986**

Between January 1, and April 12, 1986, 7,941 measles cases in Canada were reported to the Laboratory Centre for Disease Control, a greater than 20-fold increase over the corresponding period in 1985, and the largest number of measles cases reported since 1979 (Figure 1). Eight provinces reported more cases during this period than during the same period

FIGURE 1. Reported measles cases — Canada, 1976-1986

Measles — Continued

in 1985 (Table 3). British Columbia, Manitoba, and Nova Scotia accounted for 63%, 21%, and 11% of the total cases, respectively. The overall incidence rate for Canada was 31 cases per 100,000 population. British Columbia experienced the highest incidence rate (174/100,000 population) followed by Manitoba (153/100,000) and Nova Scotia (102/100,000).

Age data are available for 5,260 (98%) of the 5,367 cases reported in Canada during the first 2½ months of 1986 (Table 4). Thirty-six percent of cases occurred among 10- to 14-year-olds; 29%, among 15- to 19-year-olds; and 21%, among 5- to 9-year-olds. The highest incidence rate (104/100,000) occurred for 10- to 14-year-olds. The rate for 15- to 19-year-olds and 5- to 9-year-olds was 77 cases and 61 cases/100,000, respectively. In 1985, 10- to 14-year-olds also had the highest incidence rate (45/100,000).

TABLE 3. Reported measles cases and incidence rates,* by province and territory — Canada, January 1-April 12, 1985, and January 1 - April 12, 1986

Province/territory	1985		1986	
	No.	Rate	No.	Rate
Newfoundland	1	0.2	4	0.7
Prince Edward Island	0	0.0	0	0.0
New Brunswick	2	0.3	4	0.6
Nova Scotia	15	1.7	899	102.1
Quebec	21	0.3	12	0.6
Ontario	200	2.2	285	3.1
Manitoba	0	0.0	1,636	153.0
Saskatchewan	0	0.0	18	1.8
Alberta	42	1.8	59	2.5
British Columbia	64	2.2	5,020	173.6
Yukon	0	0.0	0	0.0
Northwest Territory	11	21.6	4	7.9
Canada	356	1.4	7,941	31.3

*Per 100,000 population.

TABLE 4. Age distribution of measles patients of known age — Canada, January-December 1985 and January 1-March 15, 1986

Age (yrs.)	1985			1986		
	No.	(%)	Rate*	No.	(%)	Rate†
< 1	142	(5.3)	37.5	105	(2.0)	27.7
1-4	315	(11.9)	21.3	386	(7.3)	26.1
5-9	666	(25.0)	37.4	1,096	(20.8)	61.5
10-14	821	(30.9)	45.3	1,893	(36.0)	104.4
15-19	593	(22.3)	30.1	1,522	(28.9)	77.1
20-24	48	(1.8)	2.0	144	(2.7)	6.0
25-29	27	(1.0)	1.2	44	(0.8)	1.9
≥30	49	(1.8)	0.4	70	(1.3)	0.5
Total	2,661	(100.0)		5,260	(100.0)	

*Per 100,000 population.

†Rate for the first 2½ months only; annual rate likely to be substantially higher.

Measles - Continued

Investigations of some of the current outbreaks in British Columbia and Manitoba indicate that approximately 73% and 55% of patients, respectively, had histories of measles vaccination. Although most patients have histories of receiving live measles vaccine, the proportion who received adequate immunization (according to current definitions) is not known. Further epidemiologic investigations are ongoing. Of interest is that, in British Columbia, between 1969 and 1974, half-doses of live measles vaccine were administered to conserve vaccine supply. In addition, many children in Canada may have received further attenuated live measles vaccine and human immune globulin simultaneously, or live attenuated measles vaccine within 6 weeks after immune globulin, killed vaccine, or vaccine at under 12 months of age.

Reported by P Varughese, S Acres, Laboratory Centre for Disease Control, Ottawa, Ontario, Canada; Div of Immunization, Center for Prevention Svcs, CDC.

Editorial Note: Measles vaccine of several types, including inactivated vaccine, has been used in Canada since 1964 (1). All provinces now routinely use further attenuated measles vaccine combined with mumps and rubella (MMR), which is recommended for use at or after 12 months of age (2). The mean annual measles incidence rate decreased from 358 cases/100,000 during the prevaccine era (1949-1958) to 30/100,000 during 1976-1985, a 92% reduction. The highest rate during the past 10 years was in 1979-95/100,000 in 1979. The lowest reported incidence occurred in 1983-4/100,000.

Measles elimination has been a priority since the early 1980s in all provinces (3). Ontario, New Brunswick, and Manitoba, representing 43% of Canada's population, introduced legislation in 1981, 1982, and 1985, respectively, making measles vaccination compulsory for school entry. Provinces without school immunization laws have used intensive education efforts to encourage vaccination and report that over 95% of children are vaccinated by the time they reach school age. The current measles outbreaks in Canada are probably attributable to accumulation of susceptibles due to unvaccinated school-aged children who started school before widespread use of measles vaccine in Canada, persons inappropriately vaccinated, and vaccine failures.

Large numbers of U.S. tourists travel to Canada each year, and more tourists than usual are expected this year because of Expo '86. Because of the large measles epidemics in several provinces of Canada, it is advisable that travelers to these areas be immune to measles. Recommendations for travelers to Canada are essentially the same as those for travelers to any area where measles is endemic or epidemic (4). A physician's documentation of prior measles disease, measles vaccination (on or after the first birthday), or laboratory evidence of immunity constitutes evidence of immunity. In the United States, measles vaccine is recommended for all children 15 months of age or older. However, the age at vaccination should be lowered for those children traveling to areas where measles is endemic or epidemic. Children 12-14 months of age may receive MMR before their departure, with no need for revaccination. Children 6-11 months of age may receive single measles antigen vaccine (without rubella or mumps antigens) before departure but must be revaccinated with MMR vaccine. The optimal age at revaccination is 15 months, although the age at revaccination may be as young as 12 months if the children remain in high-risk areas.

References

1. Larke RP. Impact of measles in Canada. *Rev Infect Dis* 1983;5:445-51.
2. National Advisory Committee on Immunization, Health and Welfare, Canada. A guide to immunization for Canadians. Ottawa, Ontario, Canada: Minister of Supply and Services, 1980.
3. White F. Policy for measles elimination in Canada. *Rev Infect Dis* 1983;5:577-82.
4. CDC. Recommendations for measles vaccination for international travel. Advisory memorandum no. 85, March 12, 1986.

Current Trends

Classification System for Human T-Lymphotropic Virus Type III/ Lymphadenopathy-Associated Virus Infections

INTRODUCTION

Persons infected with the etiologic retrovirus of acquired immunodeficiency syndrome (AIDS) (1-4)* may present with a variety of manifestations ranging from asymptomatic infection to severe immunodeficiency and life-threatening secondary infectious diseases or cancers. The rapid growth of knowledge about human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) has resulted in an increasing need for a system of classifying patients within this spectrum of clinical and laboratory findings attributable to HTLV-III/LAV infection (5-7).

Various means are now used to describe and assess patients with manifestations of HTLV-III/LAV infection and to describe their signs, symptoms, and laboratory findings. The surveillance definition of AIDS has proven to be extremely valuable and quite reliable for some epidemiologic studies and clinical assessment of patients with the more severe manifestations of disease. However, more inclusive definitions and classifications of HTLV-III/LAV infection are needed for optimum patient care, health planning, and public health control strategies, as well as for epidemiologic studies and special surveys. A broadly applicable, easily understood classification system should also facilitate and clarify communication about this disease.

In an attempt to formulate the most appropriate classification system, CDC has sought the advice of a panel of expert consultants† to assist in defining the manifestations of HTLV-III/LAV infection.

GOALS AND OBJECTIVES OF THE CLASSIFICATION SYSTEM

The classification system presented in this report is primarily applicable to public health purposes, including disease reporting and surveillance, epidemiologic studies, prevention and control activities, and public health policy and planning.

Immediate applications of such a system include the classification of infected persons for reporting of cases to state and local public health agencies, and use in various disease coding and recording systems, such as the forthcoming 10th revision of the International Classification of Diseases.

*The AIDS virus has been variously termed human T-lymphotropic virus type III (HTLV-III), lymphadenopathy-associated virus (LAV), AIDS-associated retrovirus (ARV), or human immunodeficiency virus (HIV). The designation human immunodeficiency virus (HIV) has recently been proposed by a subcommittee of the International Committee for the Taxonomy of Viruses as the appropriate name for the retrovirus that has been implicated as the causative agent of AIDS (4).

†The following persons served on the review panel: DS Burke, MD, RR Redfield, MD, Walter Reed Army Institute of Research, Washington, DC; J Chin, MD, State Epidemiologist, California Department of Health Services; LZ Cooper, MD, St Luke's-Roosevelt Hospital Center, New York City; JP Davis, MD, State Epidemiologist, Wisconsin Division of Health; MA Fischl, MD, University of Miami School of Medicine, Miami, Florida; G Friedland, MD, Albert Einstein College of Medicine, New York City; MA Johnson, MD, DI Abrams, MD, San Francisco General Hospital; D Mildvan, MD, Beth Israel Medical Center, New York City; CU Tuazon, MD, George Washington University School of Medicine, Washington, DC; RW Price, MD, Memorial Sloan-Kettering Cancer Center, New York City; C Konigsberg, MD, Broward County Public Health Unit, Fort Lauderdale, Florida; MS Gottlieb, MD, University of California—Los Angeles Medical Center; representatives of the National Institute of Allergy and Infectious Diseases, National Cancer Institute, National Institutes of Health; Center for Infectious Diseases, CDC.

*HTLV-III/LAV - Continued***DEFINITION OF HTLV-III/LAV INFECTION**

The most specific diagnosis of HTLV-III/LAV infection is by direct identification of the virus in host tissues by virus isolation; however, the techniques for isolating HTLV-III/LAV currently lack sensitivity for detecting infection and are not readily available. For public health purposes, patients with repeatedly reactive screening tests for HTLV-III/LAV antibody (e.g., enzyme-linked immunosorbent assay) in whom antibody is also identified by the use of supplemental tests (e.g., Western blot, immunofluorescence assay) should be considered both infected and infective (8-10).

Although HTLV-III/LAV infection is identified by isolation of the virus or, indirectly, by the presence of antibody to the virus, a presumptive clinical diagnosis of HTLV-III/LAV infection has been made in some situations in the absence of positive virologic or serologic test results. There is a very strong correlation between the clinical manifestations of AIDS as defined by CDC and the presence of HTLV-III/LAV antibody (11-14). Most persons whose clinical illness fulfills the CDC surveillance definition for AIDS will have been infected with the virus (12-14).

CLASSIFICATION SYSTEM

This system classifies the manifestations of HTLV-III/LAV infection into four mutually exclusive groups, designated by Roman numerals I through IV (Table 5). *The classification system applies only to patients diagnosed as having HTLV-III/LAV infection (see previous section, DEFINITION OF HTLV-III/LAV INFECTION).* Classification in a particular group is not explicitly intended to have prognostic significance, nor to designate severity of illness. However, classification in the four principal groups, I-IV, is hierarchical in that persons classified in a particular group should not be reclassified in a preceding group if clinical findings resolve, since clinical improvement may not accurately reflect changes in the severity of the underlying disease.

Group I includes patients with transient signs and symptoms that appear at the time of, or shortly after, initial infection with HTLV-III/LAV as identified by laboratory studies. All patients in Group I will be reclassified in another group following resolution of this acute syndrome.

TABLE 5. Summary of classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus

Group I.	Acute infection
Group II.	Asymptomatic infection*
Group III.	Persistent generalized lymphadenopathy*
Group IV.	Other disease
Subgroup A.	Constitutional disease
Subgroup B.	Neurologic disease
Subgroup C.	Secondary infectious diseases
Category C-1.	Specified secondary infectious diseases listed in the CDC surveillance definition for AIDS†
Category C-2.	Other specified secondary infectious diseases
Subgroup D.	Secondary cancers†
Subgroup E.	Other conditions

*Patients in Groups II and III may be subclassified on the basis of a laboratory evaluation.

†Includes those patients whose clinical presentation fulfills the definition of AIDS used by CDC for national reporting.

HTLV-III/LAV - Continued

Group II includes patients who have no signs or symptoms of HTLV-III/LAV infection. Patients in this category may be subclassified based on whether hematologic and/or immunologic laboratory studies have been done and whether results are abnormal in a manner consistent with the effects of HTLV-III/LAV infection.

Group III includes patients with persistent generalized lymphadenopathy, but without findings that would lead to classification in Group IV. Patients in this category may be subclassified based on the results of laboratory studies in the same manner as patients in Group II.

Group IV includes patients with clinical symptoms and signs of HTLV-III/LAV infection other than or in addition to lymphadenopathy. Patients in this group are assigned to *one or more* subgroups based on clinical findings. These subgroups are: A. constitutional disease; B. neurologic disease; C. secondary infectious diseases; D. secondary cancers; and E. other conditions resulting from HTLV-III/LAV infection. There is no *a priori* hierarchy of severity among subgroups A through E, and these subgroups are not mutually exclusive.

Definitions of the groups and subgroups are as follows:

Group I. Acute HTLV-III/LAV Infection. Defined as a mononucleosis-like syndrome, with or without aseptic meningitis, associated with seroconversion for HTLV-III/LAV antibody (15-16). Antibody seroconversion is required as evidence of initial infection; current viral isolation procedures are not adequately sensitive to be relied on for demonstrating the onset of infection.

Group II. Asymptomatic HTLV-III/LAV Infection. Defined as the absence of signs or symptoms of HTLV-III/LAV infection. To be classified in Group II, patients must have had no previous signs or symptoms that would have led to classification in Groups III or IV. Patients whose clinical findings caused them to be classified in Groups III or IV should not be reclassified in Group II if those clinical findings resolve.

Patients in this group may be subclassified on the basis of a laboratory evaluation. Laboratory studies commonly indicated for patients with HTLV-III/LAV infection include, but are not limited to, a complete blood count (including differential white blood cell count) and a platelet count. Immunologic tests, especially T-lymphocyte helper and suppressor cell counts, are also an important part of the overall evaluation. Patients whose test results are within normal limits, as well as those for whom a laboratory evaluation has not yet been completed, should be differentiated from patients whose test results are consistent with defects associated with HTLV-III/LAV infection (e.g., lymphopenia, thrombocytopenia, decreased number of helper [T_H] T-lymphocytes).

Group III. Persistent Generalized Lymphadenopathy (PGL). Defined as palpable lymphadenopathy (lymph node enlargement of 1 cm or greater) at two or more extra-inguinal sites persisting for more than 3 months in the absence of a concurrent illness or condition other than HTLV-III/LAV infection to explain the findings. Patients in this group may also be subclassified on the basis of a laboratory evaluation, as is done for asymptomatic patients in Group II (see above). Patients with PGL whose clinical findings caused them to be classified in Group IV should not be reclassified in Group III if those other clinical findings resolve.

Group IV. Other HTLV-III/LAV Disease. The clinical manifestations of patients in this group may be designated by assignment to one or more subgroups (A-E) listed below. Within Group IV, subgroup classification is independent of the presence or absence of lymphadenopathy. Each subgroup may include patients who are minimally symptomatic, as well as patients who are severely ill. Increased specificity for manifestations of HTLV-III/LAV infection, if needed for clinical purposes or research purposes or for disability determinations, may be achieved by creating additional divisions within each subgroup.

HTLV-III/LAV - Continued

Subgroup A. Constitutional disease. Defined as one or more of the following: fever persisting more than 1 month, involuntary weight loss of greater than 10% of baseline, or diarrhea persisting more than 1 month; and the absence of a concurrent illness or condition other than HTLV-III/LAV infection to explain the findings.

Subgroup B. Neurologic disease. Defined as one or more of the following: dementia, myelopathy, or peripheral neuropathy; and the absence of a concurrent illness or condition other than HTLV-III/LAV infection to explain the findings.

Subgroup C. Secondary infectious diseases. Defined as the diagnosis of an infectious disease associated with HTLV-III/LAV infection and/or at least moderately indicative of a defect in cell-mediated immunity. Patients in this subgroup are divided further into two categories:

Category C-1. Includes patients with symptomatic or invasive disease due to one of 12 specified secondary infectious diseases listed in the surveillance definition of AIDS[§]:

Pneumocystis carinii pneumonia, chronic cryptosporidiosis, toxoplasmosis, extra-intestinal strongyloidiasis, isosporiasis, candidiasis (esophageal, bronchial, or pulmonary), cryptococcosis, histoplasmosis, mycobacterial infection with *Mycobacterium avium* complex or *M. kansasii*, cytomegalovirus infection, chronic mucocutaneous or disseminated herpes simplex virus infection, and progressive multifocal leukoencephalopathy.

Category C-2. Includes patients with symptomatic or invasive disease due to one of six other specified secondary infectious diseases: oral hairy leukoplakia, multidermatomal herpes zoster, recurrent *Salmonella* bacteremia, nocardiosis, tuberculosis, or oral candidiasis (thrush).

Subgroup D. Secondary cancers. Defined as the diagnosis of one or more kinds of cancer known to be associated with HTLV-III/LAV infection as listed in the surveillance definition of AIDS and at least moderately indicative of a defect in cell-mediated immunity[¶]: Kaposi's sarcoma, non-Hodgkin's lymphoma (small, noncleaved lymphoma or immunoblastic sarcoma), or primary lymphoma of the brain.

Subgroup E. Other conditions in HTLV-III/LAV infection. Defined as the presence of other clinical findings or diseases, not classifiable above, that may be attributed to HTLV-III/LAV infection and/or may be indicative of a defect in cell-mediated immunity. Included are patients with chronic lymphoid interstitial pneumonitis. Also included are those patients whose signs or symptoms could be attributed either to HTLV-III/LAV infection or to another coexisting disease not classified elsewhere, and patients with other clinical illnesses, the course or management of which may be complicated or altered by HTLV-III/LAV infection. Examples include: patients with constitutional symptoms not meeting the criteria for subgroup IV-A; patients with infectious diseases not listed in subgroup IV-C; and patients with neoplasms not listed in subgroup IV-D.

Reported by Center for Infectious Diseases, CDC.

Editorial Note: The classification system is meant to provide a means of grouping patients infected with HTLV-III/LAV according to the clinical expression of disease. It will require periodic revision as warranted by new information about HTLV-III/LAV infection. The defini-

[§]This subgroup includes patients with one or more of the specified infectious diseases listed whose clinical presentation fulfills the definition of AIDS as used by CDC for national reporting.

[¶]This subgroup includes those patients with one or more of the specified cancers listed whose clinical presentation fulfills the definition of AIDS as used by CDC for national reporting.

HTLV-III/LAV - Continued

tion of particular syndromes will evolve with increasing knowledge of the significance of certain clinical findings and laboratory tests. New diagnostic techniques, such as the detection of specific HTLV-III/LAV antigens or antibodies, may add specificity to the assessment of patients infected with HTLV-III/LAV.

The classification system defines a limited number of specified clinical presentations. Patients whose signs and symptoms do not meet the criteria for other groups and subgroups, but whose findings are attributable to HTLV-III/LAV infection, should be classified in subgroup IV-E. As the classification system is revised and updated, certain subsets of patients in subgroup IV-E may be identified as having related groups of clinical findings that should be separately classified as distinct syndromes. This could be accomplished either by creating additional subgroups within Group IV or by broadening the definitions of the existing subgroups.

Persons currently using other classification systems (6-7) or nomenclatures (e.g., AIDS-related complex, lymphadenopathy syndrome) can find equivalences with those systems and terminologies and the classification presented in this report. Because this classification system has only four principal groups based on chronology, presence or absence of signs and symptoms, and the type of clinical findings present, comparisons with other classifications based either on clinical findings or on laboratory assessment are easily accomplished.

This classification system does not imply any change in the definition of AIDS used by CDC since 1981 for national reporting. Patients whose clinical presentations fulfill the surveillance definition of AIDS are classified in Group IV. However, not every case in Group IV will meet the surveillance definition.

Persons wishing to comment on this material are encouraged to send comments in writing to the AIDS Program, Center for Infectious Diseases, CDC.

References

1. Gallo RC, Salahuddin SZ, Popovic M, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. *Science* 1984;224:500-3.
2. Barré-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). *Science* 1983;220:868-71.
3. Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, Oshiro LS. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. *Science* 1984;225:840-2.
4. Coffin J, Haese A, Levy JA, et al. Human immunodeficiency viruses [Letter]. *Science* 1986;232:697.
5. CDC. Revision of the case definition of acquired immunodeficiency syndrome for national reporting—United States. *MMWR* 1985;34:373-5.
6. Haverkos HW, Gottlieb MS, Killen JY, Edelman R. Classification of HTLV-III/LAV-related diseases [Letter]. *J Infect Dis* 1985;152:1095.
7. Redfield RR, Wright DC, Tramont EC. The Walter Reed staging classification for HTLV-III/LAV infection. *N Engl J Med* 1986;314:131-2.
8. CDC. Antibodies to a retrovirus etiologically associated with acquired immunodeficiency syndrome (AIDS) in populations with increased incidences of the syndrome. *MMWR* 1984;33:377-9.
9. CDC. Update: Public Health Service Workshop on Human T-Lymphotropic Virus Type III Antibody Testing—United States. *MMWR* 1985;34:477-8.
10. CDC. Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus. *MMWR* 1986;35:152-5.
11. Selik RM, Haverkos HW, Curran JW. Acquired immune deficiency syndrome (AIDS) trends in the United States, 1978-1982. *Am J Med* 1984;76:493-500.
12. Sarngadharan MG, Popovic M, Bruch L, Schüpbach J, Gallo RC. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. *Science* 1984;224:506-8.
13. Safai B, Sarngadharan MG, Groopman JE, et al. Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome. *Lancet* 1984;i:1438-40.
14. Laurence J, Brun-Vezinet F, Schutzer SE, et al. Lymphadenopathy associated viral antibody in AIDS. Immune correlations and definition of a carrier state. *N Engl J Med* 1984;311:1269-73.


HTLV-III/LAV - Continued

15. Ho DD, Sarngadharan MG, Resnick L, Dimarzo-Veronese F, Rota TR, Hirsch MS. Primary human T-lymphotropic virus type III infection. *Ann Intern Med* 1985;103:880-3.
16. Cooper DA, Gold J, Maclean P, et al. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. *Lancet* 1985;i:537-40.

Erratum: Vol. 35, No. 17

- p. 285 In the article, "Human T-Lymphotropic Virus III/Lymphadenopathy-Associated Virus Antibody Testing at Alternate Sites," the figures in Table 5 for Colorado are incorrect. The correct figures are: Testing sites—10; Pretest sessions—4,316; Persons tested—4,316; Post-test sessions—4,316; and Percent positive—12.0.

FIGURE 1. Reported measles cases — United States, weeks 16-19, 1986



The *Morbidity and Mortality Weekly Report* is prepared by the Centers for Disease Control, Atlanta, Georgia, and available on a paid subscription basis from the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402, (202) 783-3238.

The data in this report are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the succeeding Friday.

The editor welcomes accounts of interesting cases, outbreaks, environmental hazards, or other public health problems of current interest to health officials. Such reports and any other matters pertaining to editorial or other textual considerations should be addressed to: ATTN: Editor, *Morbidity and Mortality Weekly Report*, Centers for Disease Control, Atlanta, Georgia 30333.

Director, Centers for Disease Control
James O. Mason, M.D., Dr.P.H.
Director, Epidemiology Program Office
Carl W. Tyler, Jr., M.D.

Editor
Michael B. Gregg, M.D.
Assistant Editor
Karen L. Foster, M.A.

U.S. Government Printing Office: 1986-746-149/40004 Region IV

DEPARTMENT OF
HEALTH & HUMAN SERVICES
Public Health Service
Centers for Disease Control
Atlanta GA 30333

Official Business
Penalty for Private Use \$300



Postage and Fees Paid
U.S. Dept. of H.S.
HHS 396

A 48106 48106 8446 9 X
SERIALS ACQUISITION DEPT
UNIVERSITY MICROFILMS
300 NORTH ZEEB ROAD
ANN ARBOR, MI 48106

